Axim Biotechnologies Inc represents values of innovation, integrity, and scientific excellence. As a biotechnology company, Axim Biotechnologies is committed to developing cutting-edge solutions in the field of pharmaceuticals and nutraceuticals. The company focuses on leveraging advanced research and technology to address unmet medical needs and improve patients' quality of life. Axim Biotechnologies prioritizes ethical conduct and transparency in its operations, ensuring adherence to regulatory standards and maintaining effective corporate governance. With its dedicated team of experts, Axim Biotechnologies strives to create disruptive products that positively impact the healthcare industry and benefit society as a whole.

Axim Biotechnologies Inc is primarily present in the United States.

Axim Biotechnologies Inc has achieved several significant milestones. This innovative company has made substantial progress in the field of biotechnology. Its accomplishments include developing groundbreaking therapies, receiving regulatory approvals, and securing strategic partnerships. Axim Biotechnologies Inc has successfully introduced novel pharmaceutical products, conducted successful clinical trials, and expanded its product portfolio. This company has continually strived for excellence and demonstrated its commitment to improving healthcare outcomes. Axim Biotechnologies Inc’s dedication to research and development has positioned it as a key player in the biotechnology industry, making it an attractive choice for investors looking for promising opportunities.

Axim Biotechnologies Inc is a leading biotechnology company specializing in the development of innovative therapeutics and diagnostic tests. Established in [year], the company has made significant strides in advancing breakthrough medicines for a range of medical conditions. With a focus on leveraging cutting-edge research and technologies, Axim Biotechnologies Inc has successfully developed a diverse pipeline of products targeting areas such as pain management, dermatology, oncology, and neurology. With its commitment to improving patient outcomes, the company continues to drive advancements in the biotechnology sector, delivering innovative solutions and positively impacting the lives of individuals worldwide.

The main competitors of Axim Biotechnologies Inc in the market are certain companies operating in the biotechnology sector. These include but are not limited to MediciNova Inc, GW Pharmaceuticals plc, Zogenix Inc, Zynerba Pharmaceuticals Inc, and Zynerba Pharmaceuticals Inc.

Axim Biotechnologies Inc is primarily active in the biotechnology industry.

The business model of Axim Biotechnologies Inc is focused on the research, development, and commercialization of pharmaceutical, nutraceutical, and cosmetic products. Axim Biotechnologies Inc utilizes innovative technologies and scientific expertise to create and market products derived from cannabinoids. These products aim to address various medical conditions and improve overall well-being. Axim Biotechnologies Inc combines their research capabilities with strategic partnerships and licensing agreements to drive growth and expand their product portfolio. Through their dedicated efforts in the biotechnology industry, Axim Biotechnologies Inc aims to provide effective and safe solutions for patients and consumers.

KGV-d ei saa praegu Axim Biotechnologies jaoks arvutada.

KUV-d ei ole võimalik hetkel Axim Biotechnologies jaoks arvutada.

AlleAktien kvaliteediskoor ettevõttele Axim Biotechnologies on 5/10.

Praegu ei saa Axim Biotechnologies käivet arvutada.

Praegu ei ole võimalik kasumit Axim Biotechnologies jaoks arvutada.

Axim Biotechnologies Inc is an American company specializing in biotechnological research and development in the field of medical cannabis products. The company was founded in 2014 and is headquartered in New York City. Axim Biotechnologies Inc's business model is based on three pillars: research and development, production, and distribution of medical cannabis products. The research department of Axim Biotechnologies Inc focuses on the development of new medical cannabis products that help alleviate symptoms of various diseases, such as pain, seizures, and nausea. This includes the necessary clinical testing of the products to ensure their safety and efficacy. The production department of Axim Biotechnologies Inc manufactures medical cannabis for sale to pharmacies and clinics. The company ensures that its products meet the highest safety and quality standards, which are regularly reviewed by authorities. Axim Biotechnologies Inc is also involved in the distribution of medical cannabis products. The company markets its products worldwide, primarily in countries where the use of medical cannabis is legal. There are two main products sold by Axim Biotechnologies Inc. The first product is Med-Chew RX, a chewing gum that contains medical cannabis. This product is intended for patients who suffer from chronic pain or other symptoms that cannot be sufficiently relieved by other medications. Med-Chew RX is said to have a fast and effective effect and is also discreet and easy to use. The second product is CanChew+, a chewing gum that contains cannabidiol (CBD). Cannabidiol is a component of cannabis that does not have psychoactive effects and is therefore suitable for medical purposes. The CanChew+ gum helps alleviate symptoms of anxiety and stress and also promotes cognitive function. Axim Biotechnologies Inc is also involved in researching new applications of medical cannabis. The company has entered into a collaboration with the University of British Columbia to explore an alternative, non-opioid-based pain treatment. In summary, Axim Biotechnologies Inc's business model is an innovative company specializing in the research, development, production, and marketing of medical cannabis products. The company is involved in a wide range of applications and has already introduced products to the market that can help alleviate symptoms. Axim Biotechnologies Inc aims to help patients worldwide and is committed to maintaining the highest quality standards in the industry.

Axim Biotechnologies maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Axim Biotechnologies jaoks arvutada või ettevõte ei maksa dividende välja.

Axim Biotechnologies ISIN on US05463V1008.

Axim Biotechnologies WKN on A2DF26.

Axim Biotechnologies tähis on AXIM.

Viimase 12 kuu jooksul maksis Axim Biotechnologies dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Axim Biotechnologies tõenäoliselt dividendi summas 0 USD.

Axim Biotechnologies praegune dividenditootlus on .

Axim Biotechnologies maksab kvartaalset dividendi. See makstakse välja kuudel .

Axim Biotechnologies maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

Axim Biotechnologies on liigitatud sektorisse 'Tervis'.

Viimase Axim Biotechnologies dividendide saamiseks 20.1.2025 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 20.1.2025.

Viimane dividendimakse toimus 20.1.2025.

Aastal 2024 maksis Axim Biotechnologies 0 USD dividende.

Axim Biotechnologies dividendid makstakse välja USD.